GNE-493

GNE-493 is a potent, selective, and orally bioavailable small molecule dual inhibitor of pan-phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR). Developed by Genentech, it targets all four class I PI3K isoforms (α, β, δ, and γ) as well as mTOR, effectively blocking the PI3K/AKT/mTOR signaling pathway which is frequently deregulated in various cancers. In preclinical studies, GNE-493 has demonstrated efficacy in xenograft models of cancer, including high-grade serous ovarian cancer (HGS-OvCa), where it has been used to study apoptotic vulnerabilities and drug resistance mechanisms. It is primarily utilized as a research tool compound and has not been approved for human use.

Other names

GNE 493GNE493GNE-493